Department of Pharmacology and Pharmacy, University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong.
J Pharmacol Exp Ther. 2010 Aug;334(2):373-80. doi: 10.1124/jpet.110.167098. Epub 2010 May 5.
Acute inhibition of nitric-oxide synthase (NOS) unmasks the release of endothelium-derived contracting factors (EDCFs). The present study investigated whether chronic inhibition of NOS modulates endothelium-dependent contractions. Eighteen-week-old male Sprague-Dawley rats were treated by daily gavage for 6 weeks with the NOS inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) (60 mg/kg) or vehicle (distilled water; 1 ml/kg). Chronic treatment with L-NAME increased arterial blood pressure. Isometric tension was measured in aortic rings with or without endothelium. Endothelium-dependent relaxations to acetylcholine and the calcium ionophore 5-(methylamino)-2-[(2R,3R,6S,8S,9R,11R)-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyrrol-2-yl)-ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-4-benzoxazolecarboxylic acid (A23187) were reduced in preparations from L-NAME-treated rats. The reduction in relaxation to A23187 was partially reversed by L-arginine (1 mM). In quiescent aortic rings, A23187 caused contractions in the presence of L-NAME and intact endothelium. The A23187-induced contractions were greater in rings from the L-NAME-treated rats than in those from the control group. These contractions were abolished by the cyclooxygenase (COX)-2 inhibitor N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide (NS-398) and the thromboxane-prostanoid (TP) receptor antagonist 3-((6R)-6-{[(4-chlorophenyl)sulfonyl]amido}-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)propanoate (S18886), but not by the COX-1 inhibitor 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole (SC-560). Chronic L-NAME treatment reduced the level of nitric oxide in the plasma but increased COX activity in the aortic rings. Western blotting and immunohistochemical staining showed that endothelial NOS expression was reduced in the aortae of the chronic L-NAME-treated group. COX-1 expression was augmented slightly, whereas COX-2 expression was up-regulated markedly. The TP receptor expression was comparable with control. These experiments demonstrate that chronic NOS inhibition increases endothelium-dependent contractions of the rat aorta by inducing COX-2 expression and augmenting the production of EDCF.
急性抑制一氧化氮合酶(NOS)会揭示内皮衍生收缩因子(EDCFs)的释放。本研究探讨了慢性抑制 NOS 是否会调节内皮依赖性收缩。18 周龄雄性 Sprague-Dawley 大鼠每天通过灌胃接受 6 周的 NOS 抑制剂 N(ω)-硝基-L-精氨酸甲酯(L-NAME)(60mg/kg)或载体(蒸馏水;1ml/kg)治疗。慢性 L-NAME 处理增加了动脉血压。在有或没有内皮的主动脉环中测量等长张力。乙酰胆碱和钙离子载体 5-(甲基氨基)-2-[[2R,3R,6S,8S,9R,11R]-3,9,11-三甲基-8-[[1S]-1-甲基-2-氧代-2-(1H-吡咯-2-基)-乙基]-1,7-二氧杂螺[5.5]十一烷-2-基]甲基]-4-苯并恶唑羧酸(A23187)引起的舒张反应在 L-NAME 处理大鼠的制剂中减少。L-精氨酸(1mM)部分逆转了对 A23187 的松弛反应。在静息主动脉环中,A23187 在存在 L-NAME 和完整内皮的情况下引起收缩。来自 L-NAME 处理大鼠的环中的 A23187 诱导收缩大于来自对照组的环。这些收缩被环加氧酶(COX)-2 抑制剂 N-[2-环己氧基-4-硝基苯基]甲磺酰胺(NS-398)和血栓素-前列腺素(TP)受体拮抗剂 3-((6R)-6-[[(4-氯苯基)磺酰基]氨基]-2-甲基-5,6,7,8-四氢萘-1-基)丙酸钠(S18886)消除,但 COX-1 抑制剂 5-(4-氯苯基)-1-(4-甲氧基苯基)-3-(三氟甲基)-1H-吡唑(SC-560)不能。慢性 L-NAME 处理降低了血浆中的一氧化氮水平,但增加了主动脉环中的 COX 活性。Western blot 和免疫组织化学染色显示,慢性 L-NAME 处理组主动脉内皮型一氧化氮合酶表达减少。COX-1 表达略有增加,而 COX-2 表达明显上调。TP 受体表达与对照相当。这些实验表明,慢性 NOS 抑制通过诱导 COX-2 表达和增加 EDCF 的产生来增加大鼠主动脉的内皮依赖性收缩。